Olfr1253 inhibitors are a class of chemical compounds designed to specifically target and inhibit the activity of the Olfr1253 protein, a member of the olfactory receptor family within the G-protein-coupled receptor (GPCR) superfamily. Olfr1253, like other olfactory receptors, is involved in the detection of odorant molecules and plays a critical role in the olfactory system by initiating the signal transduction processes that lead to the perception of smell. These receptors are located in the membranes of olfactory sensory neurons, where they bind to specific odorant molecules, triggering a cascade of intracellular events that ultimately result in the activation of sensory neurons and the transmission of olfactory signals to the brain. Inhibitors of Olfr1253 are typically small molecules that interact with the receptor's binding pocket or other functionally important regions, thereby preventing the receptor from binding to its natural odorant ligands. By blocking this interaction, these inhibitors can modulate the receptor's activity and alter the normal signaling pathways associated with olfactory perception.
The development of Olfr1253 inhibitors involves a detailed understanding of the receptor's structural biology and the specific molecular interactions that govern its function. Researchers often use high-throughput screening techniques to identify lead compounds that exhibit potential inhibitory effects on Olfr1253. These lead compounds are then optimized through structure-activity relationship (SAR) studies, which involve fine-tuning the chemical structure to improve binding affinity, selectivity, and metabolic stability. The chemical structures of Olfr1253 inhibitors are diverse, often incorporating functional groups that facilitate strong and specific interactions with the receptor, such as hydrogen bonds, hydrophobic contacts, and van der Waals forces. Advanced structural biology techniques, including X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy, are employed to visualize these interactions at an atomic level, providing insights that guide the design and refinement of these inhibitors. Achieving high selectivity is a critical goal in the development of Olfr1253 inhibitors, ensuring that these compounds specifically target Olfr1253 without affecting other olfactory receptors or GPCRs that may have similar structural features. This selectivity is essential for enabling precise modulation of Olfr1253 activity, allowing researchers to explore its specific role in olfactory perception and to gain a deeper understanding of the molecular mechanisms underlying the sense of smell.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
ICI 182,780 | 129453-61-8 | sc-203435 sc-203435A | 1 mg 10 mg | $83.00 $187.00 | 34 | |
Estrogen receptor antagonist, potentially disrupting estrogen receptor signaling pathways. | ||||||
Sunitinib, Free Base | 557795-19-4 | sc-396319 sc-396319A | 500 mg 5 g | $153.00 $938.00 | 5 | |
Inhibits multiple tyrosine kinases, potentially affecting angiogenesis and cell proliferation pathways. | ||||||
Anastrozole | 120511-73-1 | sc-217647 | 10 mg | $92.00 | 1 | |
Aromatase inhibitor, potentially impacting estrogen synthesis and related signaling proteins. | ||||||
XL-184 free base | 849217-68-1 | sc-364657 sc-364657A | 5 mg 10 mg | $94.00 $208.00 | 1 | |
Inhibits MET, VEGFR, and RET, potentially disrupting multiple signaling pathways. | ||||||
Lapatinib | 231277-92-2 | sc-353658 | 100 mg | $420.00 | 32 | |
Dual inhibitor of EGFR and HER2, potentially affecting proteins in associated signaling pathways. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Proteasome inhibitor, potentially affecting protein degradation and cell cycle regulation. | ||||||
Nilotinib | 641571-10-0 | sc-202245 sc-202245A | 10 mg 25 mg | $209.00 $413.00 | 9 | |
BCR-ABL tyrosine kinase inhibitor, potentially affecting proteins in leukemia signaling pathways. | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
JAK1/2 inhibitor, potentially influencing proteins in cytokine signaling pathways. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $70.00 $145.00 | 51 | |
Inhibits Src family kinases, potentially influencing proteins in cell signaling pathways. | ||||||
CH5424802 | 1256580-46-7 | sc-364461 sc-364461A | 5 mg 50 mg | $191.00 $902.00 | ||
ALK inhibitor, potentially disrupting proteins in ALK-driven signaling pathways. | ||||||